News

REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts. On July 10, REGENXBIO announced the publication of preclinical results for its investigational gene ...
PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...
The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure. A ...
The last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
After our editorial, the agency relents to allow a Duchenne treatment.
The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.
Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver ...
Sarepta Therapeutics said it will resume shipments of its gene therapy Elevidys® (delandistrogene moxeparvovec-rokl) “imminently” to ambulant patients with Duchenne muscular dystrophy (DMD), ending a ...